**CAR-T Cell Therapy as a New Option for Treating Multiple Myeloma** “CAR-T cell therapy has now become a new option for treating patients with relapsed and refractory multiple myeloma, with hopes of changing the difficult situation in myeloma treatment where treatments are either ineffective or unavailable,” said Jin Jie, Director of the Hematology Department at the Read More
China’s CAR-T Therapy: A Beacon of Hope for Children with Acute Lymphoblastic Leukemia (ALL) #CARTTherapy #Leukemia #ChildhoodCancer #ALL #CART #AcuteLymphoblasticLeukemia #Patientstory China’s CAR-T cell therapy is emerging as a beacon of hope in the fight against cancer, bringing unprecedented treatment possibilities. As a precise cellular immunotherapy, CAR-T therapy enhances the cancer-fighting abilities of T-cells through genetic editing technology, Read More
**China’s CAR-T Therapy as a Beacon of Hope: A New Light for Multiple Myeloma Patients** #CAR-TTherapy #MultipleMyeloma #PatientStory #CancerSurvivor In recent years, CAR-T cell therapy in China has spearheaded a revolution in hematologic cancer treatment. This innovative immunotherapy has brought a glimmer of hope to many patients, especially those with relapsed and refractory cases who Read More
China’s CSPC Pharmaceutical Group CAR-T Therapy: Targeted Treatment for Myasthenia Gravis #CARTTherapy #MyastheniaGravis #ChinaPharma #CSPC #CART China’s CAR-T cell therapies are attracting international attention. Recently, CSPC Pharmaceutical Group secured another clinical trial approval for a CAR-T therapy, marking a significant milestone in the treatment of autoimmune diseases. China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) officially Read More
**China’s New CAR-T Therapy: Bringing New Hope for Acute Myeloid Leukemia (AML)** #CLL1CART #AML #Leukemia #CART #CARTtherapy #AcuteMyeloidLeukemia #CLL1 #CD371 In recent years, China’s rise in the field of medical innovation has been remarkable, especially with breakthroughs in cancer and hematologic malignancy treatments that are drawing global attention. Today, we are introducing a cutting-edge treatment from China—donor-derived CLL-1 Read More
### Beacon of Hope: China’s CAR-T Therapy Helps a TP53-Deficient Diffuse Large B-Cell Lymphoma Patient Achieve Complete Remission #CAR-T #CancerTreatment #Lymphoma #DLBCL #PrecisionMedicine In an inspiring treatment case, a 38-year-old Chinese male patient with TP53-deficient Diffuse Large B-cell Lymphoma (DLBCL) achieved complete remission through Chinese CAR-T cell therapy. This remarkable outcome has sparked excitement about Read More
Chinese Scientists Achieve Major Breakthrough in Enhancing CAR-T Cell Efficacy: MEK Inhibitors Effectively Prevent CAR-T Cell Exhaustion #CARTCellTherapy #MEKInhibitors #CancerResearch #ChineseScientists #CART #MEK In recent years, CAR-T cell therapy has shown remarkable effectiveness in treating relapsed or refractory B-cell malignancies, particularly in cases where targeted therapies have failed. However, CAR-T therapy’s long-term effectiveness is often limited Read More
### Significant Progress in CAR-T Therapy in China: Long-Term Effects of Combined CD19 and CD22 Treatment for Acute B-Lymphoblastic Leukemia #ALL #CAR-Ttherapy #Leukemia #CancerResearch #B_ALL #LeukemiaTreatment Recently, a Chinese medical team published a notable study titled “Five-year outcome of CD19 combined with CD22 CAR-T cell therapy in B-ALL patients relapsed after allo-transplantation.” The research highlights Read More
**China’s CAR-T Technology Leads the World: A Miraculous Recovery Journey for Children with systemic lupus erythematosus (SLE)** #SLE #lupus #systemiclupuserythematosus #CAR_Ttherapy #CancerSurvivor #ChineseHealthcare#PatientStory In the field of medicine, the boundary between science and miracles is often blurred. This October, news from Zhejiang, China, shocked the world: 20 children suffering from refractory systemic lupus erythematosus (SLE) Read More
Another New CAR-T Therapy in China is Fast-Tracking Approval, Targeting Pediatric Acute Lymphoblastic Leukemia with a 100% Response Rate! #ALL #AcuteLymphoblasticLeukemia #Leukemia #CART #CARTtherapy In recent years, CAR-T cell therapies from China have garnered global attention in the fight against cancer, and now another CAR-T product is about to hit the market. Priscabtagene Autoleucel Injection Read More
**How to Choose Among Similar CAR-T Therapies?** Currently, there are multiple CAR-T products targeting the same antigen available on the market, which can make it difficult for patients to decide which one to choose. Experts recommend selecting a therapy based on the treatment target. It is generally advisable to prioritize approved products, as they have Read More
A 62-Year-Old Leukemia Patient in China Receives CAR-T Therapy, Discharged After One Month, and Still Healthy After Five Years! #Leukemia #CAR_Therapy #CancerSurvivor #ChineseHealthcare#PatientStory Acute lymphoblastic leukemia (ALL) is a type of leukemia that originates from B or T lymphoid progenitor cells. Leukemia cells proliferate abnormally in the bone marrow, suppressing normal hematopoiesis, leading to anemia, thrombocytopenia, and Read More
By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
© Copyright 2023 Advanced Medicine In China. All rights reserved.
